Wyeth announced that the FDA granted expanded approval for Tygacil (tigecycline), as a treatment for adults with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.

The drugmaker said the approval was based on results from two studies, which compared Tygacil to levofloxacin in patients hospitalised with CABP. The studies showed comparable cure rates for the two treatments. Wyeth's antibiotic has previously been approved in the US to treat adults with complicated skin and skin structure infections, as well as complicated intra-abdominal infections.

Reference Articles

Wyeth Pharma gets new Tygacil approval - (The Philadelphia Inquirer)

FDA approves new indication for Wyeth’s Tygacil (tigecycline) for the treatment of adult patients with community-acquired bacterial pneumonia - (Wyeth)

Wyeth gets expanded approval for antibiotic - (Yahoo!Finance)